Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
51.72
Price to sales ratio
12.76

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
107
DHR
Danaher Corporation Common Stock
216.06 USD+0.13%-0.57%+10.85%+5.54%151.89 B USD
338
NTRA
Natera, Inc. - Common Stock
326.26 USD-3.67%-0.65%+29.27%+96.47%47.03 B USD
364
A
Agilent Technologies, Inc. Common Stock
153.77 USD-2.36%-1.56%+10.36%+24.16%43.43 B USD
367
IQV
IQVIA Holdings, Inc. Common Stock
261.73 USD-0.21%+1.94%+7.27%+38.40%43.08 B USD

Frequently asked questions about Idexx Laboratories Inc

What is the Idexx Laboratories Inc stock price today?

The current price of Idexx Laboratories Inc (IDXX) is 554.99. Over the past 24 hours, the stock has changed by +1.82%. Follow the IDXX chart for real-time price dynamics.

What is the stock ticker of Idexx Laboratories Inc?

Idexx Laboratories Inc trades under the ticker IDXX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Idexx Laboratories Inc stock going up?

IDXX has changed by -0.72% over the last week, -1.24% over the last month, and -12.88% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Idexx Laboratories Inc?

Idexx Laboratories Inc currently has a market capitalization of 43.72 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Idexx Laboratories Inc earnings last quarter?

Last quarter, Idexx Laboratories Inc reported earnings of 4.29 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Idexx Laboratories Inc revenue for the last quarter?

Idexx Laboratories Inc reported quarterly revenue of 1.21 B. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Idexx Laboratories Inc net income for the last quarter?

Idexx Laboratories Inc reported net income of 338.41 M for the last quarter. The previous quarter showed 278.45 M, which means net income changed by +21.54%.

How many employees does Idexx Laboratories Inc have?

As of the latest available data, Idexx Laboratories Inc has 11 K employees. Workforce size can provide additional context about the company's scale and operations.

What is Idexx Laboratories Inc EBITDA?

Idexx Laboratories Inc EBITDA is 461.95 M, and its EBITDA margin is 38.04%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Idexx Laboratories Inc stock?

You can buy Idexx Laboratories Inc (IDXX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Idexx Laboratories Inc stock?

Investing in Idexx Laboratories Inc requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the IDXX chart and related analysis on metatrader.com as part of your research.

IDEXX Laboratories, Inc. - Common Stock

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions. IDEXX offers products to customers in over 175 countries around the world and employs approximately 9,200 people in full-and part-time positions. There are three main segments of the company: Companion Animal Group, Water, and Livestock, Poultry and Dairy. In addition, the company also manufactures and sells pet-side SNAP tests for a variety of animal health diagnostic uses. In 2002, Jon Ayers succeeded company founder Shaw as chairman and CEO. During Ayers 20-year tenure, the company's annual revenue grew from $380 million to $3 billion, raising share prices by more than 100 times. In 2019, Jay Mazelsky succeeded Ayers in the role of CEO.

News